|
The outcome of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or NOS compared to DLBCL patients from a single institution. |
|
Joanna Romejko-Jarosinska |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Roche; Takeda |
|
|
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Hospira; Roche; Sandoz; Sanofi |
|
|
Travel, Accommodations, Expenses - Roche; Sandoz |
|
|
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
Anna P. Dabrowska-Iwanicka |
Travel, Accommodations, Expenses - Genzyme; Roche |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Sanofi |
|
|
Travel, Accommodations, Expenses - Stainwei Biotech |
|
|
Travel, Accommodations, Expenses - Roche |
|
Monika Prochorec-Sobieszek |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Gilead Sciences; Janssen-Cilag; Roche; Servier; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Incyte; Janssen-Cilag; Roche |
Research Funding - Bayer/Onyx (Inst); Celgene (Inst); Celltrion (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche; Sanofi; SERVIER |